Marshall Richard Peter 4

What Happened

• Marshall Richard Peter, a director of Serina Therapeutics (SER), made an open-market purchase of 12,183 common shares on May 19, 2026. The filing reports a weighted-average purchase price of $1.65 per share for a total transaction value of approximately $20,102. This was a direct purchase (transaction code P), which investors often view as a more positive signal than a sale.

Key Details

• Transaction date: 2026-05-19; Filing date: 2026-05-22.
• Shares acquired: 12,183 at a weighted-average price of $1.65; total ≈ $20,102.
• Price range: purchases occurred at prices between $1.59 and $1.73 per share (weighted avg disclosed). Footnote: upon written request from the SEC or the issuer/securityholder, the reporting person will provide the number of shares bought at each price.
• Shares owned after the transaction: not specified in the information provided.
• Timeliness: the Form 4 was filed three calendar days after the transaction (Form 4s are typically required within two business days), which may indicate a late filing.

Context

• This was a straightforward open-market purchase (no option exercise, gift, or tax withholding involved). Purchases by insiders can be of interest to retail investors as they show the insider increasing exposure to the company, but they do not by themselves explain motivation or future company prospects.